Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
NF-κB/AP-1 Inhibitor
IQ-1S is an inhibitor of NF-κB and activating protein 1 (AP-1), exhibiting an IC50 of 1.8 μM. It demonstrates significant binding affinity for all three JNK isoforms, with Kd values of 87 nM for JNK3, 360 nM for JNK2, and 390 nM for JNK1. IQ-1S is valuable for researchers investigating the role of JNK signaling pathways and their implications in inflammation and cancer. -
JNK2 Inhibitor
JNK2-IN-1 is a selective inhibitor of JNK2, displaying a dissociation constant (Kd) of 79.2 μM. This compound exhibits anti-inflammatory properties by reducing the secretion of pro-inflammatory cytokines TNF-α and IL-6 through the inhibition of the NF-κB/MAPK signaling pathway. JNK2-IN-1 has demonstrated therapeutic potential in alleviating symptoms associated with LPS-induced acute lung injury (ALI) and sepsis, making it valuable for research in inflammation and related diseases. -
NF-κB p65 Inhibitor, p38 MAPK Inhibitor
PSMα3 is an inhibitor of NF-κB p65 and p38 MAPK, playing a significant role in modulating inflammatory pathways. This compound forms membrane pores and interacts with the human insulin B chain, inhibiting insulin aggregation and contributing to cytotoxic effects through α-type amyloid-like fibril formation. PSMα3 is valuable for research on spondyloarthritis, rheumatoid arthritis, insulin-derived amyloidosis, and infections caused by Staphylococcus aureus. -
NF-κB/MAPK Inhibitor
NF-κB/MAPK-IN-1 is a potent inhibitor of the NF-κB and MAPK signaling pathways, exhibiting significant biological activity in the modulation of inflammatory responses. It effectively reduces nitric oxide (NO) production with an IC50 of 6.96 µM and inhibits the activation of iNOS, COX-2, ERK, and p38 signaling pathways induced by LPS. This compound is valuable for research applications focused on inflammatory diseases, including rheumatoid arthritis. -
NF-κB/MMP9/MAPK Inhibitor
Isoliquiritin apioside is an inhibitor of NF-κB, MMP9, and MAPK signaling pathways. It has been shown to significantly reduce PMA-induced MMP9 activity and suppress the activation of MAPK and NF-κB. This compound is relevant for research applications focused on cancer biology, particularly in the investigation of mechanisms underlying cell invasiveness and angiogenesis in both cancer and endothelial cells. -
PDE4 Inhibitor
Glaucine, a selective phosphodiesterase 4 (PDE4) inhibitor, is an alkaloid sourced from Glaucium flavum. It demonstrates significant biological activities such as bronchodilation, anti-inflammatory effects, and anticancer properties. With a Ki of 3.4 µM in human bronchial tissues and polymorphonuclear leukocytes, Glaucine promotes relaxation of isolated human bronchi through calcium channel antagonism. Furthermore, it inhibits NF-κB activation, which downregulates MMP-9 expression, thereby impairing the migration and invasion of breast cancer cells. Glaucine is relevant for research applications in asthma and breast cancer. -
PDE4 Inhibitor
LT-104A is a selective phosphodiesterase 4 (PDE4) inhibitor that effectively elevates intracellular cyclic AMP (cAMP) levels, exhibiting an EC50 of 1.9 μM and inhibiting PDE4D3 activity with an IC50 of 9.3 μM. By activating the cAMP-PKA-CREB anti-inflammatory signaling pathway, LT-104A suppresses expression of NF-κB-related genes such as Il1b and Nos2. This compound is valuable for research focused on inflammation-related diseases and therapeutic interventions aimed at modulating inflammatory responses. -
PI3K/Akt Inhibitor, MAPK Inhibitor, NF-κB Inhibitor, Nrf2/ARE Activator
JRN73958 is a potent inhibitor of the PI3K/Akt, MAPK, and NF-κB signaling pathways. This compound effectively reduces LPS/IFNγ-induced activation of these pathways, making it a valuable tool for investigating their roles in cancer biology, particularly in leukemia research. Additionally, JRN73958 acts as an Nrf2/ARE activator, further expanding its utility in studies related to oxidative stress and cell survival mechanisms. -
p38 MAPK Inhibitor
Ganoderterpene A is a potent inhibitor of p38 MAPK, demonstrating significant anti-inflammatory and anti-apoptotic activity. It effectively attenuates LPS-induced inflammation and apoptosis by suppressing the MAPK and TLR-4/NF-κB signaling pathways in BV-2 cells. This compound is valuable for research applications focused on neuroinflammation and cellular stress responses. -
MAPK/NF-κB Inhibitor
Masticadienonic acid is a selective inhibitor of the MAPK pathway (including p38, ERK, and JNK) and the NF-κB signaling cascade, while also acting as an agonist of the Nrf2 pathway. This compound effectively reduces the release of proinflammatory cytokines such as TNFα, IL-1β, and IL-6, and it restores the expression of intestinal tight junction proteins, including ZO-1 and occludin. Its regulatory effects on intestinal flora and inflammation make it suitable for research applications in inflammatory bowel disease and leishmaniasis. -
NF-κB/MAPK Inhibitor
Isonardosinone is a nardosinone-type sesquiterpene that primarily targets the NF-κB and MAPK signaling pathways. It effectively inhibits the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in lipopolysaccharide-induced BV2 microglial cells, demonstrating significant anti-inflammatory activity. This compound is valuable for research applications focused on inflammation and neurodegenerative diseases. -
p38 MAPK Inhibitor
Anti-inflammatory agent 7 is a selective p38 MAPK inhibitor that modulates the NF-κB/MAPK signaling pathway to inhibit proinflammatory cytokine production. This reagent demonstrates significant anti-inflammatory activity in LPS-treated RAW 264.7 cells and in in vivo models, making it a valuable tool for studying inflammatory responses and developing therapeutic strategies for related diseases. -
MyD88 Inhibitor
T6167923 is a selective inhibitor of MyD88-dependent signaling pathways, targeting the Toll/IL-1 receptor (TIR) domain of MyD88 to disrupt its homodimeric formation. This compound effectively inhibits NF-κB-mediated Staphylococcus enterotoxin AP (SEAP) activity, demonstrating notable anti-inflammatory effects with IC50 values of 2.7 μM for IFN-γ, 2.9 μM for IL-1β, 2.66 μM for IL-6, and 2.66 μM for TNF-α. T6167923 serves as a valuable tool in studying the role of MyD88 signaling in inflammatory responses and therapeutic interventions. -
Myd88 Inhibitor
MyD88-IN-1 is a potent inhibitor of MyD88, targeting the interaction between TLR4 and MyD88. By suppressing the NF-κB signaling pathway, MyD88-IN-1 demonstrates significant biological activity relevant to cancer and inflammatory research. This compound serves as a valuable tool for elucidating the role of MyD88 in various disease processes and therapeutic interventions. -
Influenza Virus Inhibitor
Amizon is an orally effective antiviral agent targeting the influenza virus. It inhibits viral replication and restricts RNA synthesis, while simultaneously reducing the mRNA expression of pro-inflammatory mediators such as COX-1, COX-2, NF-κB, TGF-β1, IL-1, and IL-6. Additionally, Amizon enhances the secretion and mRNA expression of the anti-inflammatory cytokine IL-10 and exhibits antioxidant properties, inhibiting the oxidative activity of macrophages. This compound is of interest in research focused on influenza and acute respiratory viral infections. -
Parasite Inhibitor
8-Deoxygartanin, a prenylated xanthone derived from Garcinia mangostana, serves as a selective inhibitor of butyrylcholinesterase (BChE). This compound demonstrates significant antiplasmodial activity, with an IC50 value of 11.8 μM against the W2 strain of Plasmodium falciparum. Additionally, 8-Deoxygartanin inhibits NF-κB (p65) activation, displaying an IC50 of 11.3 μM, making it a valuable reagent for research in parasitic infections and inflammation pathways. -
Syk Inhibitor
DBMB is a selective inhibitor of spleen tyrosine kinase (Syk) that effectively attenuates Syk kinase activity. Its mechanism of action involves the suppression of NF-κB signaling, leading to a decrease in the production of key inflammatory mediators, including nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB is suitable for investigations focused on inflammatory diseases and elucidating the role of Syk in immune response pathways. -
iNOS Inhibitor
Asperuloside is an iridoid compound derived from Hedyotis diffusa, primarily known for its role as an inducible nitric oxide synthase (iNOS) inhibitor. This compound exhibits notable anti-inflammatory properties by suppressing the NF-κB and MAPK signaling pathways. Asperuloside is valuable in studying inflammatory processes and developing therapeutic strategies for related diseases. -
NF-κB Inhibitor
Neocryptotanshinone is a potent NF-κB inhibitor derived from Salvia miltiorrhiza. This compound effectively suppresses lipopolysaccharide-induced inflammation by targeting and inhibiting the NF-κB and iNOS signaling pathways. It shows promise in research applications focused on inflammatory diseases and provides valuable insights into the mechanisms of immune response modulation. -
iNOS/Nf-Κb Inhibitor
Hymenoxin is a dual inhibitor of inducible nitric oxide synthase (iNOS) and nuclear factor kappa B (NF-κB), exhibiting IC50 values of 42.7 μM and 85.5 μM, respectively. This compound demonstrates the capacity to reduce oxidative stress by 16% at a concentration of 125 μg/mL. Hymenoxin is primarily utilized in research focused on inflammatory responses and related signaling pathways. Its inhibitory effects on key regulators make it valuable for studies investigating the roles of iNOS and NF-κB in various disease models. -
NOS Inhibitor
SDMA (p-hydroxyazobenzene-p′-sulfonate) is a potent endogenous inhibitor of nitric oxide synthase (NOS), making it a valuable tool for studying NOS-related pathways. This compound has been shown to activate NF-κB, leading to increased expression of pro-inflammatory cytokines such as IL-6 and TNF-α. Additionally, SDMA demonstrates stability in serum and plasma, allowing its use as a biomarker for assessing hepatic and renal dysfunction in various research applications. -
iNOS/ICAM-1 Inhibitor
Aloenin aglycone is an inhibitor of iNOS and ICAM-1, derived from aloe exudate. It effectively suppresses TNFα-induced NF-κB transcriptional activity with an IC50 of 18.7 μM. Additionally, at a concentration of 10 μM, it significantly reduces the expression of both inducible nitric oxide synthase (iNOS) and intercellular adhesion molecule 1 (ICAM-1) in HepG2 cells following TNFα stimulation. This compound serves as a valuable tool for investigating inflammatory pathways and potential therapeutic interventions in related conditions. -
FOXP3 Inhibitor
Peptide P60 is a potent FOXP3 inhibitor that disrupts the nuclear translocation of FOXP3, thereby decreasing its regulatory effects on NF-κB and NFAT signaling pathways. This action inhibits the immunosuppressive capabilities of regulatory T cells, facilitating the proliferation and activation of effector T cells. Experimental studies have shown that Peptide P60 can induce lymphoproliferative autoimmune syndrome in neonatal ICR mice and diminish the population of CD4+CD25+Foxp3+ T cells in the spleen. Additionally, it enhances the efficacy of peptide vaccines and recombinant adenovirus-based vaccines, making it valuable for research in tumor immunology, viral infections, and autoimmune conditions. -
RANKL Inhibitor
RANKL-IN-1 is a selective and orally bioactive inhibitor of Receptor Activator of Nuclear Factor-κB Ligand (RANKL), displaying a KD value of 7.6 μM. This compound effectively inhibits osteoclastogenesis with an IC50 of 0.07 μM and a selectivity index of 82.57. RANKL-IN-1 directly interacts with RANKL, preventing downstream activation of the NF-κB and MAPK signaling pathways. It is a valuable tool for investigating metabolic disorders, particularly osteoporosis. -
STING Inhibitor
STING-IN-4 is a potent STING inhibitor that effectively reduces the expression and activation of STING and nuclear factor-κB (NF-κB) signaling pathways. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for investigating sepsis and related inflammatory conditions. Researchers can utilize STING-IN-4 to explore the therapeutic potential of modulating STING activity in various biological contexts. -
NF-κB Inhibitor
Eupenicisirenin C is a potent inhibitor of the NF-κB signaling pathway. This compound effectively suppresses the cGAS-STING pathway, demonstrating significant potential in modulating inflammatory responses. Notably, Eupenicisirenin C inhibits RANKL-induced osteoclast differentiation in bone marrow macrophages, making it a valuable tool for research into bone metabolism and inflammatory diseases. -
BACH1 Inhibitor
ASP-8731 is a potent BACH1 inhibitor that enhances NRF2-mediated gene transcription, thereby activating antioxidant and anti-inflammatory pathways. This compound significantly upregulates the expression of key genes such as HMOX1 and FTH1, and increases fetal hemoglobin (HbF) levels, promoting F-cell production in hydroxyurea-unresponsive cells. Additionally, ASP-8731 mitigates inflammatory responses by downregulating VCAM1, ICAM-1, and NF-κB (p65) phosphorylation. Its ability to relieve glutathione depletion and microcirculatory stasis suggests potential applications in the treatment of sickle cell disease and other hematological disorders. -
COX-2 Inhibitor
COX-2-IN-51 is a selective COX-2 inhibitor exhibiting an IC50 of 70.7 nM. It effectively reduces LPS-induced release of nitric oxide (NO) and prostaglandin E2 (PGE2), as well as the expression of COX-2 and inducible nitric oxide synthase (iNOS), and inhibits the NF-κB signaling pathway. This compound demonstrates anti-inflammatory and analgesic properties in various murine models by targeting the NF-κB cascade, while presenting a lower risk of gastrointestinal side effects compared to traditional nonsteroidal anti-inflammatory drugs. -
COX-2/15-LOX Inhibitor
COX-2/15-LOX-IN-5 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and 15-lipoxygenase (15-LOX). This compound effectively attenuates lipopolysaccharide-induced NF-κB activation in RAW 264.7 macrophages, highlighting its role in modulating inflammatory responses. COX-2/15-LOX-IN-5 exhibits significant anti-inflammatory and antioxidant properties, making it a valuable tool for research into inflammatory diseases and other related biological processes. -
COX-2/TAK1-NF-κB Inhibitor
BPD is a selective inhibitor of COX-2 and TAK1-NF-κB, exhibiting an IC50 of 18.5 μM for COX-2. This compound effectively reduces the transcriptional expression of key pro-inflammatory cytokines, including iNOS, TNF-α, IL-6, and IL-1β, thereby demonstrating notable anti-inflammatory properties. BPD has been shown to inhibit carrageenan-induced paw edema and mitigate LPS-induced septic mortality, making it a valuable tool for research in inflammation and related pathways. -
NF-κB/COX Inhibitor
Methoxycoronarin D is a potent inhibitor of NF-κB, demonstrating an IC50 value of 7.3 μM. Additionally, it selectively inhibits cyclooxygenase-1 (COX-1), with an IC50 value of 0.9 μM. This compound is relevant for research applications focused on inflammation and cancer due to its ability to modulate critical signaling pathways. -
COX-2 Inhibitor
Cavidine is a selective COX-2 inhibitor that exhibits potent anti-inflammatory properties. It is particularly useful in research concerning skin injuries, hepatitis, cholecystitis, and scabies. Additionally, Cavidine has been shown to alleviate LPS-induced acute lung injury through modulation of the NF-κB signaling pathway, making it a valuable compound for studying inflammation-related conditions. -
PAK1 Inhibitor
AK963/40708899 is a selective inhibitor of PAK1, disrupting the PAK1-NF-κB-cyclinB1 signaling pathway. This compound effectively suppresses the proliferation of human gastric cancer cells and induces G2 phase cell cycle arrest, consequently reducing migration and invasion. Additionally, AK963/40708899 inhibits filopodia formation and enhances cell adhesion, negatively regulating the PAK1-LIMK-cofilin and PAK1-ERK-FAK pathways, thereby diminishing the invasive potential of gastric cancer cells. This reagent is valuable for research into cancer biology and therapeutic interventions targeting PAK1 signaling pathways. -
Sphingomyelinase Inhibitor, K-Ras Inhibitor, H-Ras Inhibitor, NF-κB Inhibitor
Avicin G is a potent inhibitor of sphingomyelinases, specifically targeting neutral sphingomyelinases (SMPD2/3) and acid sphingomyelinase (SMPD1). This compound elevates intracellular sphingomyelin levels and modulates the distribution of sphingomyelin, disrupting signal transduction pathways in oncogenic K-Ras and H-Ras. Avicin G exhibits significant biological activity, including the reduction of ERK and Akt phosphorylation and alterations in lysosomal pH. Its applications extend to research on pancreatic ductal adenocarcinoma and non-small cell lung cancer. -
AP-1/NF-κB Activation Inhibitor
SPC 839 is an orally active inhibitor that targets AP-1 and NF-κB mediated transcriptional activation, demonstrating an IC50 of 0.008 μM. This compound is essential for studying pathways associated with inflammation, cancer progression, and cellular stress responses. Its potent inhibition of key transcription factors makes it a valuable tool for researchers investigating the role of AP-1 and NF-κB in various biological processes. -
NF-κB Inhibitor
Ganoderic acid H is a lanostane-type triterpene that functions as an NF-κB inhibitor. It effectively suppresses the growth and invasive behavior of breast cancer cells by inhibiting the activity of transcription factors AP-1 and NF-κB. This compound holds potential for research applications in cancer biology, particularly for studies focusing on the modulation of signaling pathways involved in tumor progression and metastasis. -
NF-κB/AP-1 Inhibitor
Glucocorticoid receptor modulator 1 is a selective non-steroidal modulator that targets the glucocorticoid receptor, exhibiting potent inhibition of NF-κB and AP-1 with IC50 values of 9 nM and 130 nM, respectively. This compound effectively reduces the expression of key inflammatory cytokines, including IL-6, IL-1β, and TNF-α. Additionally, it demonstrates potential in alleviating dermatitis in preclinical models, making it a valuable tool for research in inflammation and immune response. -
COX Inhibitor
Inulicin (1-O-Acetylbritannilactone) is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically targeting COX-2 activity. This compound demonstrates significant biological activity by inhibiting lipopolysaccharide (LPS)-induced production of prostaglandin E2 (PGE2) as well as the expression of COX-2. Additionally, Inulicin suppresses NF-κB activation and its translocation, making it valuable for research applications related to inflammation and cancer. -
MARCKS Inhibitor
BIO-11006 is a specific inhibitor of the MARCKS protein, known for its role in modulating inflammatory responses. This peptide attenuates lipopolysaccharide (LPS)-induced neutrophil influx into lung tissues, suppresses NF-κB activation, and reduces the expression of proinflammatory cytokines such as KC and TNF-α. BIO-11006 has demonstrated efficacy in reversing disease progression in an LPS-induced mouse model of lung injury, making it a valuable tool for research into acute lung injury and acute respiratory distress syndrome (ALI/ARDS). -
NF-κB Inhibitor
Demethyleneberberine chloride is an NF-κB inhibitor that exhibits significant anti-inflammatory properties. This compound has been shown to alleviate colitis in murine models by modulating inflammatory responses through inhibition of the NF-κB pathway and regulation of T helper cell balance. Additionally, Demethyleneberberine chloride acts as an AMPK activator, making it a valuable reagent for research into non-alcoholic fatty liver disease (NAFLD). -
NF-κB Inhibitor, GPx Inhibitor, HIV Replication Inhibitor
α-MSH (11-13) acetate is a selective melanocortin-1 receptor ligand that functions as an inhibitor of NF-κB, GPx activity, and HIV replication. It induces an acute elevation of intracellular calcium levels under certain costimulation or pathway inhibition conditions. This compound effectively suppresses TNF-α-induced NF-κB activation, inhibits colony formation of Staphylococcus aureus and Candida albicans, and demonstrates potential in the study of infections related to these pathogens, as well as in traumatic brain injury, corneal epithelial wounds, and inflammatory bowel disease research. -
Na+/K+-ATPase Inhibitor
(-)-γ-Cuparenol is a sesquiterpene compound that acts as an inhibitor of Na+/K+-ATPase, with an IC50 value of 23.6 μg/mL in porcine models. It has demonstrated the ability to reduce phytohemagglutinin (PHA)-induced activation of NF-AT and NF-κB in Jurkat cells, indicating potential applications in immunoregulation. Additionally, (-)-γ-Cuparenol exhibits antibacterial activity against certain Gram-positive and some Gram-negative bacteria, as well as weak inhibitory effects on Candida albicans. This compound is relevant for research exploring cardiovascular diseases and bacterial infections. -
Bacterial Inhibitor/Anti-inflammatory Agent
Cyclo(L-Pro-L-Val) is a peptide-based compound that functions as a bacterial inhibitor and anti-inflammatory agent. It exhibits antimicrobial activity against plant pathogens, such as R. fascians, and demonstrates significant inhibition of critical signaling molecules like IKKα, IKKβ, NF-κB, iNOS, and COX-2, contributing to its anti-inflammatory properties. This compound is valuable for research applications in developing biopesticides and investigating inflammation-related diseases. -
TrxR1 Inhibitor
Evernic Acid is a potent inhibitor of thioredoxin reductase 1 (TrxR1), demonstrating significant antiproliferative effects on human breast cancer cells. It disrupts the NF-κB signaling pathway by preventing p65 nuclear translocation and IκBα phosphorylation, which subsequently reduces inflammatory mediators. In addition to its role as an antioxidant and neuroprotective agent, Evernic Acid protects neurons from oxidative stress and mitochondrial dysfunction. Furthermore, it inhibits key enoyl reductases in Plasmodium falciparum and downregulates quorum sensing and biofilm formation in Pseudomonas aeruginosa, showcasing its antibacterial and antifungal properties. This compound is valuable for research focused on breast cancer, neurodegenerative diseases, and microbial infections. -
PKC Inhibitor
PKC-IN-4 is a selective inhibitor of atypical protein kinase C (aPKC) with an IC50 of 0.52 µM. This compound effectively inhibits TNF-α-induced NF-κB signaling in vitro, making it a valuable tool for studies involving inflammatory responses. Additionally, PKC-IN-4 has been shown to block VEGF- and TNF-α-induced permeability across the retinal vasculature, highlighting its potential in retinal disease research and vascular permeability exploration. -
Survivin Inhibitor
Isonanangenine B is a selective inhibitor of survivin, exhibiting an IC50 of 1.6 µM. It effectively obstructs the interaction of critical transcription factors, including Stat3 and NF-κB, with the survivin promoter. This compound holds potential for advancing cancer research, particularly in elucidating the mechanisms of survivin modulation in tumorigenesis. -
TNF-α/NF-κB Inhibitor
TNF-α-IN-28 is a selective inhibitor of TNF-α and NF-κB, demonstrating significant anti-inflammatory activity. This compound effectively inhibits the expression of both TNF-α and NF-κB by targeting the TNF-α dimer. TNF-α-IN-28 is intended for use in research applications focused on inflammation, immune response modulation, and related signaling pathways. -
cGAS Inhibitor
cGAS-IN-9 is an inhibitor of cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) with IC50 values of 27.5 nM and 5.15 μM for human and murine cGAS, respectively. This compound demonstrates weak inhibitory activity against human soluble adenylate cyclase, with an IC50 of 26.4 μM. cGAS-IN-9 significantly reduces dsDNA-induced expression of IFNB1 and CXCL10, as well as inhibits the activation of the NF-κB pathway in human immune cells. It is a valuable tool for research on cGAS-dependent inflammatory diseases. -
Proteasome Inhibitor
PR-39 is a natural proline- and arginine-rich antibacterial peptide that functions as a noncompetitive, reversible allosteric inhibitor of the proteasome. By binding to the α7 subunit of the proteasome, PR-39 effectively blocks the degradation of NF-κB inhibitor IκBα through the ubiquitin-proteasome pathway. This compound demonstrates key biological activities such as stimulating angiogenesis and inhibiting inflammatory responses, making it a valuable tool for research on myocardial infarction and inflammatory diseases. -
CTH/H2S/NF-κB/EMT Inhibitor
TKL002 is a selective inhibitor targeting the CTH/H2S/NF-κB/EMT signaling pathway, proven to penetrate the blood-brain barrier. It effectively induces G2/M phase cell cycle arrest and apoptosis in glioblastoma cells, simultaneously inhibiting their migration and invasion. This compound upregulates E-cadherin while downregulating N-cadherin and vimentin, making it a valuable tool for investigative studies in glioblastoma research.
